Parmax Pharma Ltd. benchmarking: Perfomance to industry peers

Financial

	Parmax Pharma	Beryl Drugs	Colinz Laboratories
Operational Metrics
Financials
5 yr Average ROE	-1068.03 %	3.64 %	4.71 %
5yr average Equity Multiplier	29.23	2.12	1.29
5yr Average Asset Turnover Ratio	1.05	1.19	0.64
5yr Avg Net Profit Margin	-11.29 %	1.13 %	5.84 %
Price to Book	0.0	1.27	1.11
P/E	0.0	49.39	23.16
5yr Avg Cash Conversion Cycle	-92.25 Days	-589.78 Days	-11.59 Days
Inventory Days	69.37 Days	36.09 Days	56.66 Days
Days Receivable	20.01 Days	112.55 Days	42.5 Days
Days Payable	296.94 Days	964.25 Days	89.1 Days
5yr Average Interest Coverage Ratio	-0.77	1.91	11.55
5yr Avg ROCE	-14.3 %	7.2 %	6.71 %
5yr Avg Operating Profit Margin	2.43 %	6.72 %	7.54 %
5 yr average Debt to Equity	10.96	0.59	0.07
5yr CAGR Net Profit	n/a	19.3 %	18.95 %
5yr Average Return on Assets	-9.05 %	1.98 %	3.68 %
Shareholdings
Promoter Holding	30.8 %	26.38 %	66.0 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	1.46 %	0.07 %
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0